MARKET

MYMD

MYMD

MyMD Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.000
+0.020
+0.50%
Opening 15:06 01/27 EST
OPEN
4.320
PREV CLOSE
3.980
HIGH
4.390
LOW
3.950
VOLUME
155.08K
TURNOVER
--
52 WEEK HIGH
10.48
52 WEEK LOW
3.300
MARKET CAP
150.56M
P/E (TTM)
-3.2927
1D
5D
1M
3M
1Y
5Y
MyMD Pharma secures new U.S. patent covering MYMD-1 in a method of treating sarcopenia
MyMD Pharmaceuticals (MYMD) announces that the USPTO has awarded the company Patent No. 11,219,620 B2, titled “Method of Treating Sarcopenia.” The patent will be issued on January 11, 2022. The
Seekingalpha · 01/05 14:43
MyMD Pharmaceuticals Announces Issuance Of New US Patent Covering MYMD-1 In A Method Of Treating Sarcopenia
Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and extending healthy lifespan, 16 patents in total BALTIMORE--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc.
Benzinga · 01/05 14:21
BRIEF-Mymd Pharmaceuticals Investment Company Oravax Medical Signs Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10 Million Doses Of Oral Covid-19 Vaccine To Be Commercialized In Southeast Asia
reuters.com · 12/29/2021 14:23
MyMD Pharmaceuticals Highlights Investment Company Oravax Medical's Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10M Doses Of Oral COVID-19 Vaccine To Be Commercialized In Southeast Asia
In addition to pre-purchase order, parties have agreed to negotiate potential follow-on orders that could be significant MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a
Benzinga · 12/29/2021 14:16
From Benzinga's Global Small Cap Conference: Lexaria Bioscience, Head Of IR, George Jurcic Begins Presenting
https://www.youtube.com/watch?v=B-z-9eznBMU
Benzinga · 12/08/2021 14:27
Mymd Pharmaceuticals Inc (MYMD) EVP of Operations, GC Paul Rivard Bought $90,450 of Shares
GuruFocus News · 11/25/2021 14:15
MyMD Pharma expands IP portfolio with another patent win for lead asset
MyMD Pharmaceuticals (MYMD -1.0%) announced that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent with the number 11,179,382 B2 for its lead candidate MYMD-1 today. The patent
Seekingalpha · 11/23/2021 15:03
BRIEF-MyMD Pharma Announces Issuance Of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
reuters.com · 11/23/2021 14:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYMD. Analyze the recent business situations of MyMD Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MYMD stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 4.010
EPS
Actual
Estimate
-0.61-0.46-0.30-0.15
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 41
Institutional Holdings: 5.94M
% Owned: 15.78%
Shares Outstanding: 37.64M
TypeInstitutionsShares
Increased
8
157.49K
New
8
1.42M
Decreased
6
516.31K
Sold Out
2
68.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.33%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Lead Director/Independent Director
Joshua Silverman
President/Director
Chris Chapman
Chief Financial Officer
Ian Rhodes
Executive Vice President/General Counsel
Paul Rivard
Chief Scientific Officer
Adam Kaplin
Director
Craig Eagle
Director
Jude Uzonwanne
Independent Director
Bill White
No Data
About MYMD
MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Webull offers kinds of MyMD Pharmaceuticals Inc stock information, including NASDAQ:MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.